Poster Abstracts • OFID 2018:5 (Suppl 1) • S555 pump refilled each day at an outpatient infusion center. All seven patients were infected with P. aeruginosa (four being MDR) with one patient co-infected with E. coli. Susceptibility testing was performed on three P. aeruginosa isolates (two susceptible and one intermediate Methods. We created a survey of eight patient scenarios culled from the OPAT records of Tufts Medical Center. Six case scenarios had clinical equipoise, while two control scenarios had a clear indication for discharge with intravenous antibiotics. Infectious diseases attendings affiliated with Tufts Medical Center were surveyed. Respondents were asked preferences for oral vs. intravenous antibiotics for each scenario, their confidence in each decision, and demographics. Providers' antibiotic scores equaled the sum of responses to the six case scenarios (1 point for intravenous, 0 points for oral). Self-assessments of confidence in each decision were on a scale of 0 to 100% (100% indicating complete confidence).
Background. Hospital admission is a key cost driver in ABSSSI patients. Data suggest many ABSSSI patients are unnecessarily hospitalized and can be effectively and safely managed as outpatient (OP) at substantially lower cost. ORI a single-dose treatment has the potential to shift care from the inpatient (IP) to the OP setting in selected patients. In phase III trials, a single dose of ORI had comparable efficacy and safety to twice daily VAN for 7-10 days in ABSSSI patients who were treated in OP. Real-world comparative data on outcomes in ABSSSI patients using ORI in OP are limited. This study sought to compare the 30 day hospital admission rates and mean (standard deviation (SD)) healthcare costs among ABSSSI patients who received ORI or VAN as an OP. Results. In 2016, 120 and 6,695 patients who received ORI and VAN, respectively, met inclusion criteria. Groups were well balanced at baseline (table) . ORI patients had a significantly lower 30 d admission rate vs. VAN patients (5.8% vs. 16.2%, respectively, P = 0.002). Mean (SD) cost 30 d post index were comparable between ORI and VAN patients ($10,096 (8,865) vs. 12,779 (28,773) , respectively, P = 0.3).
Methods. Retrospective cohort analysis of ORI and VAN patients in the Truven

Conclusion.
Results suggest ORI provides a single-dose alternative to multi-dose VAN 
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